Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Quarterly figures for Telomir Pharmaceuticals, Inc., with source filings when available.
14 quarters. Mar 31, 2023 to Jun 30, 2026. mixed units.
Telomir Pharmaceuticals, Inc. has filed its 10-Q within 41 to 45 days of period end across its last 8 quarters. The 10-K runs 35 to 89 days.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | |||||||||
| Q2 2026 | Jun 30, 2026 | — | Aug 13, 2026 | 44 d | 10-Q | — | — | -$0.79 | |
| Q1 2026 | Mar 31, 2026 | — | May 14, 2026 | 44 d | 10-Q | — | — | -$0.03 | |
| FY 2025 | |||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 17, 2026 | 76 d | 10-K | — | — | — | |
| Q3 2025 | Sep 30, 2025 | — | Nov 10, 2025 | 41 d | 10-Q | ||||
| FY 2024 | |||||||||
| Q4 2024derived | Dec 31, 2024 | — | Feb 4, 2025 | 35 d | 10-K | — | — | — | |
| Q3 2024 | Sep 30, 2024 | — | Nov 12, 2024 | 43 d | 10-Q | ||||
| FY 2023 | |||||||||
| Q4 2023 | Dec 31, 2023 | — | Mar 29, 2024 | 89 d | 10-K | — | — | — | |
| Q3 2023 | Sep 30, 2023 | — | — | — | — | — | — | -$0.06 | |
| — |
| — |
| -$0.03 |
| Q2 2025 | Jun 30, 2025 | — | Aug 14, 2025 | 45 d | 10-Q | — | — | -$0.17 |
|---|
| Q1 2025 | Mar 31, 2025 | — | May 14, 2025 | 44 d | 10-Q | — | — | -$0.07 |
|---|
| — |
| — |
| -$0.20 |
| Q2 2024 | Jun 30, 2024 | — | Aug 13, 2024 | 44 d | 10-Q | — | — | $0.05 |
|---|
| Q1 2024 | Mar 31, 2024 | — | May 13, 2024 | 43 d | 10-Q | — | — | -$0.23 |
|---|
| Q2 2023 | Jun 30, 2023 | — | — | — | — | — | — | -$0.06 |
|---|
| Q1 2023 | Mar 31, 2023 | — | — | — | — | — | — | -$0.02 |
|---|
